Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.

ABSTRACT:

Introduction

Anaemia is a common complication of chronic kidney disease (CKD). Owing to the limitations of erythropoiesis-stimulating agents (ESAs), the current standard of care, there is a need to develop new therapies. Hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors might be a promising new treatment option. Molidustat is an oral HIF-PH inhibitor that stimulates the endogenous, predominantly renal, production of erythropoietin and was generally well tolerated in phase IIb clinical trials. Here, we report the design and rationale of two studies from the molidustat phase III programme: MolIdustat once dailY improves renal Anaemia By Inducing erythropoietin (MIYABI).

Methods and analysis

MIYABI Non-Dialysis-Correction (ND-C) and MIYABI Non-Dialysis-Maintenance

SUBMITTER: Yamamoto H 

PROVIDER: S-EPMC6588957 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature